Fed. Cir.

Gilead Sciences, Inc. v. Merck & Co., Inc., No. 16-2302 (Fed. Cir. Apr. 25, 2018)

Errata

Court: U.S. Court of Appeals for the Federal Circuit
Case No.: No. 16-2302
Also Docketed: No. 16-2615 (consolidated; same document)
Decided: April 25, 2018
Judge: —
Document: Errata
Length: 1 page

Full Text Analysis Cite this Opinion

Download Opinion (PDF)

United States Court of Appeals

for the Federal Circuit

April 26, 2018

ERRATUM

Appeal Nos. 2016-2302, 2016-2615

GILEAD SCIENCES, INC.,

Plaintiff-Cross-Appellant

MERCK & CO., INC., MERCK SHARP & DOHME

CORP., ISIS PHARMACEUTICALS, INC.,

Defendants-Appellants Decided: April 25, 2018 Precedential Opinion

Please make the following change: On page 2, line 21, “Solvadi®” is changed to “Sovaldi®”

Text extracted from the official PDF and reflowed for reading. It is not a certified transcript — the PDF linked above is the authoritative document.

Analysis is coming soon.

A plain-English account of the issues, facts and holding, written by Patent Case Watch. The opinion itself — its full text, its PDF and everything else on this page — stays free to read for everyone, always.

Cite this opinion

Gilead Sciences, Inc. v. Merck & Co., Inc., No. 16-2302 (Fed. Cir. Apr. 25, 2018).

govinfo ID: USCOURTS-ca13-16-02302-1
Permalink: https://patentcasewatch.com/opinions/USCOURTS-ca13-16-02302-1

No reporter citation is shown because the official source does not supply one; none is inferred here. Check the opinion and a citator before relying on this form.

Source: govinfo.gov USCOURTS collection · retrieved July 25, 2026 · Report an error